Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Group 1 - Ligand Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025, and will hold a conference call at 8:30 AM ET to discuss the results and provide a business update [1][2] - The company operates a business model focused on generating value for stockholders through a diversified portfolio of biotech and pharmaceutical product revenue streams, supported by a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization to generate revenue [3] Group 2 - Ligand's Captisol® platform technology optimizes the solubility and stability of drugs, while the NITRICIL™ platform technology allows for tunable dosing and adjustable drug release profiles [3] - The company has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]